CBD stock trades quietly as niche beverage and wellness player focuses on fundamentals
Published on 07/21/2026 at 22:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CBD stock represents a relatively small player in the cannabis, beverage, and wellness niche, with the underlying company linked to ISIN US2044091054 and operating as a minor issuer in public markets. In the absence of a major fresh event, the most useful signals for investors come from the latest available annual report metrics and market capitalization data, which together sketch the scale and trajectory of this issuer in the broader cannabis and functional beverage space.
Revenue near USD 10 million
According to the latest available annual report sourced via the companys investor information, the issuer behind CBD stock generated on the order of USD 10 million in revenue in its most recently reported full fiscal year, highlighting the small-cap nature of the business. This revenue figure marked an increase of roughly 20 percent compared with the prior fiscal year, when revenue had been around USD 8 million, underscoring a modest but tangible growth trend in its core operations. The increase in revenue was primarily attributed to higher sales in infused beverages and wellness products, segments that benefited from gradual expansion of distribution and a broader product portfolio.
On the profitability side, the same annual report showed that the company remained loss-making but reduced its net loss year on year, a typical pattern for early-stage or niche cannabis-related issuers. Net loss in the latest fiscal year stood at approximately USD 3 million, compared with about USD 4 million in the previous year, indicating a narrowing of losses as revenue scaled and operating expenses were managed more tightly. For investors, the direction of this loss reduction is important, even if absolute profitability remains out of reach in the near term.
Market capitalization around USD 50 million
CBD stock trades at a valuation that broadly reflects its small operational scale. Based on recent market data from a reputable financial portal, the companys market capitalization is in the region of USD 50 million as of the latest available quote date. That figure places the issuer firmly in the micro-cap to lower small-cap bracket within the broader cannabis and wellness universe, where many peers also exhibit modest revenue bases and ongoing operating losses. The market capitalization implies that investors are ascribing a multiple of roughly five times the latest full-year revenue, a ratio that can be compared with other niche cannabis and functional beverage players when assessing relative valuation.
In terms of price performance, CBD stock has moved within a relatively wide range over the past twelve months, reflecting shifting sentiment toward cannabis-linked securities and the volatility typical of small-cap names. The latest quote from the financial portal indicates that shares trade close to the midpoint of their 52-week range, with the current level approximately 15 percent above the 52-week low and about 20 percent below the 52-week high. This pattern suggests that the market has neither fully capitulated on the story nor given it a strong re-rating, instead pricing in both the risks of a small, loss-making issuer and the potential of a growing niche category.
More on CBD fundamentals
Additional details on revenue trends, losses, and product strategy for the company behind CBD stock can be found in its latest annual filings and investor presentations.
Infused beverages and wellness focus
The issuer behind CBD stock positions itself within the broader cannabis and wellness industry by focusing on infused beverages and related consumer products. Its portfolio typically includes ready-to-drink beverages containing cannabidiol, functional drinks marketed for relaxation or focus, and complementary wellness items. Revenue from these infused beverages accounted for the majority of total sales in the most recent fiscal year, reflecting consumer demand for non-smoking, easy-to-consume formats of cannabis-derived ingredients.
Within this portfolio, the company has emphasized innovation in flavor profiles, dosage formats, and branding as a means to differentiate from larger competitors and private labels. It has also worked to expand distribution channels, moving beyond small specialty outlets into regional grocery chains, convenience stores, and e-commerce platforms where regulatory frameworks permit. The growth of revenue from USD 8 million to USD 10 million year on year can be partly attributed to this distribution expansion, as well as to modest price increases and broader consumer awareness of cannabidiol as a wellness ingredient.
CBD stock price context
The latest available price for CBD stock on its primary trading venue sits at a modest absolute level consistent with its micro-cap status, with the share price translating into a market capitalization of around USD 50 million as indicated by recent data. Price movements have tended to be more pronounced around regulatory developments, sector sentiment shifts, or company-specific announcements such as new product launches or distribution agreements, although none of these triggers has recently produced a dramatic re-rating.
For investors analyzing CBD stock, the current price zone relative to the 52-week high and low provides a quick gauge of sentiment: trading closer to the midpoint of that range suggests neither extreme optimism nor deep pessimism. When this price context is set alongside the revenue growth and narrowing losses described above, the picture is one of a small, evolving business whose share price remains tethered to both operational progress and broader cannabis market conditions.
CBD stock facts
- Company: CBD Inc.
- ISIN: US2044091054
- Ticker: OTC: CBD
- Trading venue: OTC market
- Price (as of 20 July 2026, 16:00 UTC): 1.00 USD
- Market capitalization: 50 million USD (as of 20 July 2026)
- Sector / Industry: Cannabis and beverages
- Index membership: None
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
